Stock Yards Bank & Trust Co. Has $1.81 Million Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Stock Yards Bank & Trust Co. raised its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 123.4% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,253 shares of the company's stock after purchasing an additional 1,797 shares during the period. Stock Yards Bank & Trust Co.'s holdings in IDEXX Laboratories were worth $1,806,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently bought and sold shares of the stock. OFI Invest Asset Management acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter worth about $25,000. Valley National Advisers Inc. increased its position in IDEXX Laboratories by 84.6% during the fourth quarter. Valley National Advisers Inc. now owns 48 shares of the company's stock worth $26,000 after buying an additional 22 shares during the period. Geo Capital Gestora de Recursos Ltd acquired a new position in IDEXX Laboratories during the third quarter worth approximately $28,000. Covestor Ltd increased its position in IDEXX Laboratories by 71.8% during the third quarter. Covestor Ltd now owns 67 shares of the company's stock worth $29,000 after buying an additional 28 shares during the period. Finally, Whittier Trust Co. of Nevada Inc. increased its position in IDEXX Laboratories by 108.6% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 73 shares of the company's stock worth $32,000 after buying an additional 38 shares during the period. Institutional investors and hedge funds own 87.84% of the company's stock.

Insider Transactions at IDEXX Laboratories

In other news, SVP George Fennell sold 8,198 shares of the business's stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares of the company's stock, valued at $3,851,815.44. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In related news, SVP George Fennell sold 8,198 shares of the company's stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $573.87, for a total value of $4,704,586.26. Following the completion of the transaction, the senior vice president now directly owns 6,712 shares in the company, valued at $3,851,815.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Brian P. Mckeon sold 23,326 shares of the company's stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total value of $13,296,053.26. Following the completion of the transaction, the chief financial officer now owns 29,718 shares of the company's stock, valued at $16,939,557.18. The disclosure for this sale can be found here. Insiders sold a total of 43,524 shares of company stock valued at $24,871,960 over the last three months. 2.18% of the stock is currently owned by insiders.

IDEXX Laboratories Price Performance

IDXX stock traded up $14.23 during midday trading on Tuesday, hitting $493.80. 558,366 shares of the stock were exchanged, compared to its average volume of 430,752. The stock's 50-day moving average price is $536.30 and its 200-day moving average price is $510.27. The stock has a market cap of $41.01 billion, a price-to-earnings ratio of 47.62, a PEG ratio of 3.67 and a beta of 1.26. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, February 5th. The company reported $2.32 earnings per share for the quarter, topping analysts' consensus estimates of $2.12 by $0.20. IDEXX Laboratories had a return on equity of 71.66% and a net margin of 23.08%. The company had revenue of $901.60 million during the quarter, compared to analysts' expectations of $891.88 million. During the same period in the previous year, the firm posted $2.05 earnings per share. The business's revenue for the quarter was up 8.8% compared to the same quarter last year. Research analysts predict that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

Wall Street Analyst Weigh In

IDXX has been the topic of several research analyst reports. Piper Sandler lowered IDEXX Laboratories from an "overweight" rating to a "neutral" rating and set a $525.00 price target on the stock. in a research report on Tuesday, January 30th. The Goldman Sachs Group lifted their target price on IDEXX Laboratories from $500.00 to $650.00 and gave the company a "buy" rating in a research note on Wednesday, January 17th. JPMorgan Chase & Co. lifted their target price on IDEXX Laboratories from $600.00 to $630.00 and gave the company an "overweight" rating in a research note on Tuesday, February 6th. William Blair restated an "outperform" rating on shares of IDEXX Laboratories in a research note on Tuesday, April 9th. Finally, Barclays lifted their price target on IDEXX Laboratories from $605.00 to $655.00 and gave the company an "overweight" rating in a research note on Tuesday, February 6th. Three analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, IDEXX Laboratories has an average rating of "Moderate Buy" and a consensus target price of $591.50.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.